XBIO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

639.16K

-12.3%

629.65K

+2.53%

690.12K

+6.26%

Estimates Revision

The market is revising No Change the revenue expectations for Xenetic Biosciences, Inc. (XBIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -76.90%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-76.90%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Xenetic Biosciences Inc (XBIO.O) is -0.72, compared to its 5-year average forward P/E of -2.90. For a more detailed relative valuation and DCF analysis to assess Xenetic Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.90

Current PE

-0.72

Overvalued PE

-1.17

Undervalued PE

-4.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.06

Current EV/EBITDA

-0.15

Overvalued EV/EBITDA

1.10

Undervalued EV/EBITDA

-0.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

8.28

Current PS

1.67

Overvalued PS

17.64

Undervalued PS

-1.09

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XBIO News & Events

Events Timeline

No data

News

2.0

2025-10-08TipRanks

What’s Driving the Rise of Pharmaceutical Stocks XBIO, UPC, XTLB, and ACXP Today?

9.5

2025-08-12NASDAQ.COM

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

9.0

2025-03-13Business Insider

Xenetic presents preclinical data on DNase I with CAR T cells in murine model

People Also Watch

Frequently Asked Questions

What is Xenetic Biosciences Inc (XBIO) stock price today?

The current price of XBIO is 2.185 USD — it has increased 0.78 % in the last trading day.

What is Xenetic Biosciences Inc (XBIO)'s business?

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.

What is the price predicton of XBIO Stock?

Wall Street analysts forecast XBIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XBIO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Xenetic Biosciences Inc (XBIO)'s revenue for the last quarter?

Xenetic Biosciences Inc revenue for the last quarter amounts to 1.03M USD, increased 67.19 % YoY.

What is Xenetic Biosciences Inc (XBIO)'s earnings per share (EPS) for the last quarter?

Xenetic Biosciences Inc. EPS for the last quarter amounts to -0.33 USD, increased 17.86 % YoY.

What changes have occurred in the market's expectations for Xenetic Biosciences Inc (XBIO)'s fundamentals?

How many employees does Xenetic Biosciences Inc (XBIO). have?

Xenetic Biosciences Inc (XBIO) has 2 emplpoyees as of January 09 2026.

What is Xenetic Biosciences Inc (XBIO) market cap?

Today XBIO has the market capitalization of 5.01M USD.